DK1520175T3 - Oncolytiske vira som midler til fænotypebestemmelse af neoplasmer - Google Patents
Oncolytiske vira som midler til fænotypebestemmelse af neoplasmerInfo
- Publication number
- DK1520175T3 DK1520175T3 DK03737795T DK03737795T DK1520175T3 DK 1520175 T3 DK1520175 T3 DK 1520175T3 DK 03737795 T DK03737795 T DK 03737795T DK 03737795 T DK03737795 T DK 03737795T DK 1520175 T3 DK1520175 T3 DK 1520175T3
- Authority
- DK
- Denmark
- Prior art keywords
- neoplasms
- agents
- oncolytic viruses
- phenotype determination
- phenotype
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 244000309459 oncolytic virus Species 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/14—Reoviridae, e.g. rotavirus, bluetongue virus, Colorado tick fever virus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39203102P | 2002-06-28 | 2002-06-28 | |
| US44318803P | 2003-01-29 | 2003-01-29 | |
| PCT/CA2003/000951 WO2004003562A2 (fr) | 2002-06-28 | 2003-06-25 | Virus oncolytiques en tant qu'agents de phenotypage destines a des neoplasmes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1520175T3 true DK1520175T3 (da) | 2008-02-11 |
Family
ID=30003222
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK03737795T DK1520175T3 (da) | 2002-06-28 | 2003-06-25 | Oncolytiske vira som midler til fænotypebestemmelse af neoplasmer |
| DK07021569.4T DK1890151T3 (da) | 2002-06-28 | 2003-06-25 | Onkolytiske vira som midler til fænotypebestemmelse for neoplasmer |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK07021569.4T DK1890151T3 (da) | 2002-06-28 | 2003-06-25 | Onkolytiske vira som midler til fænotypebestemmelse for neoplasmer |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US7306902B2 (fr) |
| EP (2) | EP1890151B1 (fr) |
| JP (1) | JP2005531306A (fr) |
| CN (1) | CN1666105B (fr) |
| AR (1) | AR039768A1 (fr) |
| AT (2) | ATE555388T1 (fr) |
| AU (2) | AU2003245760B2 (fr) |
| BR (1) | BR0311983A (fr) |
| CA (1) | CA2487824C (fr) |
| DE (1) | DE60317331T2 (fr) |
| DK (2) | DK1520175T3 (fr) |
| ES (2) | ES2292981T3 (fr) |
| HK (2) | HK1069877A1 (fr) |
| IL (2) | IL165498A0 (fr) |
| MX (1) | MXPA04012414A (fr) |
| NZ (1) | NZ537116A (fr) |
| PT (1) | PT1890151E (fr) |
| SI (1) | SI1890151T1 (fr) |
| TW (3) | TWI327167B (fr) |
| WO (1) | WO2004003562A2 (fr) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPQ425699A0 (en) | 1999-11-25 | 1999-12-23 | University Of Newcastle Research Associates Limited, The | A method of treating a malignancy in a subject and a pharmaceutical composition for use in same |
| US8491884B2 (en) | 2000-05-03 | 2013-07-23 | Oncolytics Biotech Inc. | Virus clearance of neoplastic cells from mixed cellular compositions |
| US7306902B2 (en) * | 2002-06-28 | 2007-12-11 | Oncolyties Biotech Inc. | Oncolytic viruses as phenotyping agents for neoplasms |
| US20040115170A1 (en) * | 2001-11-30 | 2004-06-17 | Brown Earl Garnet | Oncolytic virus |
| AU2003249059A1 (en) | 2002-07-24 | 2004-02-09 | Arizona Board Of Regents | Use of vaccinia virus deleted for the e3l gene as a vaccine vector |
| AU2002953436A0 (en) | 2002-12-18 | 2003-01-09 | The University Of Newcastle Research Associates Limited | A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis |
| WO2005007824A2 (fr) * | 2003-07-08 | 2005-01-27 | Arizona Board Of Regents | Mutants du virus vaccine tenant lieu d'agents oncolytiques |
| WO2005111200A1 (fr) * | 2004-05-17 | 2005-11-24 | Universite De Montreal | Souches de reovirus et procedes d'utilisation de celles-ci |
| WO2007099401A2 (fr) | 2005-08-01 | 2007-09-07 | University Technologies International, Inc. | Reovirus attenue |
| US10668119B2 (en) | 2005-08-01 | 2020-06-02 | Virocure, Inc. | Attenuated reovirus |
| ATE516370T1 (de) * | 2005-12-22 | 2011-07-15 | Sloan Kettering Inst Cancer | Verfahren zur erfassung von krebszellen unter verwendung eines virus |
| AU2007215328A1 (en) * | 2006-02-13 | 2007-08-23 | Oncolytics Biotech Inc. | Use of local immune suppression to enhance oncolytic viral therapy |
| US10369171B2 (en) | 2007-03-13 | 2019-08-06 | Virocure, Inc. | Attenuated reoviruses for selection of cell populations |
| WO2008144067A1 (fr) * | 2007-05-21 | 2008-11-27 | Board Of Regents, University Of Texas System | Procédés et compositions pour le traitement du cancer en utilisant l'activité oncolytique vrs |
| KR101585702B1 (ko) * | 2008-05-22 | 2016-01-15 | 제일약품주식회사 | 종양파괴 바이러스 요법에 대한 과다증식성 세포의 종양 억제인자-기초된 민감성 |
| JP2011520994A (ja) * | 2008-05-27 | 2011-07-21 | オンコリティクス バイオテク，インコーポレーテッド | 腫瘍崩解性レオウイルス療法中の炎症性サイトカイン産生の排除 |
| TW200951143A (en) * | 2008-05-27 | 2009-12-16 | Oncolytics Biotech Inc | Modulating interstitial pressure and oncolytic viral delivery and distribution |
| US8481297B2 (en) * | 2009-01-08 | 2013-07-09 | Yale University | Compositions and methods of use of an oncolytic vesicular stomatitis virus |
| ES2385251B1 (es) | 2009-05-06 | 2013-05-06 | Fundació Privada Institut D'investigació Biomèdica De Bellvitge | Adenovirus oncolíticos para el tratamiento del cáncer. |
| US9428565B2 (en) | 2011-01-31 | 2016-08-30 | The General Hospital Corporation | Treatment and bioluminescent visualization using multimodal TRAIL molecules |
| WO2013052915A2 (fr) | 2011-10-05 | 2013-04-11 | Genelux Corporation | Procédé de détection de la réplication ou colonisation d'un produit thérapeutique biologique |
| WO2013138522A2 (fr) | 2012-03-16 | 2013-09-19 | Genelux Corporation | Méthodes d'évaluation de l'efficacité et de la surveillance d'un traitement viral oncolytique |
| WO2013158265A1 (fr) | 2012-04-20 | 2013-10-24 | Genelux Corporation | Méthodes d'imagerie pour virothérapie oncolytique |
| EP3473708B1 (fr) | 2012-07-24 | 2021-01-27 | The General Hospital Corporation | Traitement par virus oncolytique de tumeurs résistantes |
| US9605074B2 (en) | 2012-08-30 | 2017-03-28 | The General Hospital Corporation | Multifunctional nanobodies for treating cancer |
| US20140140959A1 (en) | 2012-10-05 | 2014-05-22 | Aladar A. Szalay | Energy Absorbing-Based Diagnostic and Therapeutic Methods Employing Nucleic Acid Molecules Encoding Chromophore-Producing Enzymes |
| US20160303174A1 (en) * | 2013-12-11 | 2016-10-20 | The General Hospital Corporation | Stem cell delivered oncolytic herpes simplex virus and methods for treating brain tumors |
| WO2015103438A2 (fr) | 2014-01-02 | 2015-07-09 | Genelux Corporation | Traitement d'appoint par un virus oncolytique avec des agents qui augmentent l'infectivité du virus |
| EA201700181A1 (ru) | 2014-10-14 | 2017-09-29 | Галозим, Инк. | Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования |
| EP3261669B1 (fr) | 2015-02-25 | 2022-08-03 | Memorial Sloan Kettering Cancer Center | Utilisation de virus de la vaccine ankara modifié (mva) non réplicatif inactivé en tant que mono-immunothérapie ou en association avec des agents de blocage de point de contrôle pour des tumeurs solides |
| US10548930B2 (en) | 2015-04-17 | 2020-02-04 | Memorial Sloan Kettering Cancer Center | Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors |
| CN109152827B (zh) | 2016-02-25 | 2023-07-21 | 纪念斯隆凯特琳癌症中心 | 重组mva或表达人flt3l的mvaδe3l及其作为抗固体肿瘤的免疫治疗剂的用途 |
| SG11201807051VA (en) | 2016-02-25 | 2018-09-27 | Memorial Sloan Kettering Cancer Center | Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy |
| WO2017181152A2 (fr) | 2016-04-15 | 2017-10-19 | Alpine Immune Sciences, Inc. | Protéines immunomodulatrices à variants de cd80 et leurs utilisations |
| SG11201808457PA (en) | 2016-04-15 | 2018-10-30 | Alpine Immune Sciences Inc | Icos ligand variant immunomodulatory proteins and uses thereof |
| WO2017205674A1 (fr) | 2016-05-25 | 2017-11-30 | Arizona Board Of Regents On Behalf Of Arizona State University | Mutants de virus oncolytiques de la vaccine et leur utilisation pour le traitement du cancer |
| US11834490B2 (en) | 2016-07-28 | 2023-12-05 | Alpine Immune Sciences, Inc. | CD112 variant immunomodulatory proteins and uses thereof |
| EP3491013A1 (fr) | 2016-07-28 | 2019-06-05 | Alpine Immune Sciences, Inc. | Protéines immunomodulatrices à variants de cd155 et leurs utilisations |
| US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
| CN109982708B (zh) * | 2016-09-27 | 2023-05-23 | 萨特治疗学有限公司 | 优化的溶瘤病毒及其用途 |
| EP3872180A1 (fr) | 2016-10-20 | 2021-09-01 | Alpine Immune Sciences, Inc. | Protéines immunomodulatrices sécrétables de type variant et thérapie cellulaire utilisant des cellules obtenues par génie génétique |
| US11920156B2 (en) | 2017-02-09 | 2024-03-05 | Indapta Therapeutics, Inc. | Engineered natural killer (NK) cells and compositions and methods thereof |
| AU2018235838B2 (en) | 2017-03-16 | 2023-12-14 | Alpine Immune Sciences, Inc. | CD80 variant immunomodulatory proteins and uses thereof |
| KR20240039221A (ko) | 2017-03-16 | 2024-03-26 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Pd-l1 리간드 변이체 면역조절 단백질 및 그의 용도 |
| AU2018235835A1 (en) | 2017-03-16 | 2019-09-05 | Alpine Immune Sciences, Inc. | PD-L2 variant immunomodulatory proteins and uses thereof |
| US11242509B2 (en) | 2017-05-12 | 2022-02-08 | Memorial Sloan Kettering Cancer Center | Vaccinia virus mutants useful for cancer immunotherapy |
| US20200283500A1 (en) | 2017-10-18 | 2020-09-10 | Alpine Immune Sciences, Inc. | Variant icos ligand immunomodulatory proteins and related compositions and methods |
| KR102662837B1 (ko) | 2018-06-04 | 2024-05-03 | 카리디 바이오테라퓨틱스, 인크. | 바이러스 치료법의 강화를 위한 세포-기반 비히클 |
| US11505782B2 (en) | 2018-06-04 | 2022-11-22 | Calidi Biotherapeutics, Inc. | Cell-based vehicles for potentiation of viral therapy |
| US20210363219A1 (en) | 2018-06-15 | 2021-11-25 | Alpine Immune Sciences, Inc. | Pd-1 variant immunomodulatory proteins and uses thereof |
| EP3844276A2 (fr) | 2018-08-28 | 2021-07-07 | Actym Therapeutics, Inc. | Souches bactériennes immunostimulatrices modifiées et utilisations associées |
| EP3876951A1 (fr) | 2018-11-06 | 2021-09-15 | Calidi Biotherapeutics, Inc. | Systèmes améliorés pour thérapie virale oncolytique à médiation cellulaire |
| US20220008466A1 (en) | 2018-11-21 | 2022-01-13 | Indapta Therapeutics, Inc | Methods for expansion of natural killer (nk) cell subset and related compositions and methods |
| KR20210135987A (ko) | 2018-11-30 | 2021-11-16 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Cd86 변이체 면역조절 단백질 및 그의 용도 |
| CA3176660A1 (fr) | 2019-02-27 | 2020-09-03 | Actym Therapeutics, Inc. | Bacteries immunostimulatrices modifiees en vue de coloniser des tumeurs, des cellules immunitaires residant dans une tumeur et le microenvironnement tumoral |
| JP2023523429A (ja) | 2020-04-22 | 2023-06-05 | インダプタ セラピューティクス インコーポレイテッド | ナチュラルキラー（ｎｋ）細胞組成物およびそれを生成させるための方法 |
| WO2022147480A1 (fr) | 2020-12-30 | 2022-07-07 | Ansun Biopharma, Inc. | Virus oncolytique codant pour la sialidase et agent de ciblage de cellule immunitaire multispécifique |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5747469A (en) * | 1991-03-06 | 1998-05-05 | Board Of Regents, The University Of Texas System | Methods and compositions comprising DNA damaging agents and p53 |
| US5670330A (en) * | 1992-09-29 | 1997-09-23 | Mcgill University | Anti-tumor agent assay using PKR |
| AU682854B2 (en) | 1993-02-16 | 1997-10-23 | Onyx Pharmaceuticals | Cytopathic viruses for therapy and prophylaxis of neoplasia |
| US5801029A (en) | 1993-02-16 | 1998-09-01 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
| DK1314431T3 (da) | 1993-04-30 | 2008-11-10 | Wellstat Biologics Corp | Oprensede sammensætninger af Newcastle disease virus |
| CA2178902A1 (fr) | 1993-12-14 | 1995-06-22 | Drew Pardoll | Liberation controlee de substances pharmaceutiquement actives pour l'immunotherapie |
| WO1995032300A1 (fr) | 1994-05-23 | 1995-11-30 | University Of Medicine & Dentistry Of New Jersey | Destruction biologique selective des cellules tumorales |
| US5585096A (en) | 1994-06-23 | 1996-12-17 | Georgetown University | Replication-competent herpes simplex virus mediates destruction of neoplastic cells |
| US5840502A (en) | 1994-08-31 | 1998-11-24 | Activated Cell Therapy, Inc. | Methods for enriching specific cell-types by density gradient centrifugation |
| US6777177B1 (en) * | 1997-10-10 | 2004-08-17 | Vanderbilt University | Mammalian genes involved in viral infection and tumor suppression |
| US6136307A (en) * | 1997-08-13 | 2000-10-24 | Oncolytics Biotech Inc. | Reovirus for the treatment of cellular proliferative disorders |
| CA2508238C (fr) | 1997-08-13 | 2008-01-15 | Oncolytics Biotech Inc. | Reovirus pour le traitement des neoplasies |
| US6110461A (en) | 1997-08-13 | 2000-08-29 | Oncolytics Biotech Inc. | Reovirus for the treatment of neoplasia |
| US7780962B2 (en) * | 1997-10-09 | 2010-08-24 | Wellstat Biologics Corporation | Treatment of neoplasms with RNA viruses |
| NZ518945A (en) | 1997-10-09 | 2007-03-30 | Wellstat Biologics Corp | Treatment of neoplasms with viruses |
| US6475481B2 (en) | 1997-11-18 | 2002-11-05 | Canji Inc | Purging of stem cell products |
| EP1061806A4 (fr) | 1998-03-12 | 2001-09-12 | Univ Pennsylvania | Cellules productrices pour virus aptes a la replication utilisees dans le traitement de la malignite |
| ATE318176T1 (de) | 1998-08-31 | 2006-03-15 | Julian L Ambrus | Verfahren zur entfernung von hiv und anderen viren aus blut |
| EP1390046A4 (fr) | 1999-04-15 | 2005-04-20 | Wellstat Biologics Corp | Traitement de neoplasmes avec des virus |
| DE19934788B4 (de) * | 1999-07-27 | 2004-05-27 | T-Mobile Deutschland Gmbh | Verfahren zur automatischen Anpassung von Daten an die Fähigkeiten einer Nutzer-Software |
| NZ517573A (en) | 1999-09-17 | 2004-02-27 | Pro Virus Inc | Sequences of the oncolytic virus strain vesicular stromatitis virus (VSV) |
| AU782020B2 (en) | 1999-11-12 | 2005-06-30 | Oncolytics Biotech, Inc. | Viruses for the treatment of cellular proliferative disorders |
| AUPQ425699A0 (en) | 1999-11-25 | 1999-12-23 | University Of Newcastle Research Associates Limited, The | A method of treating a malignancy in a subject and a pharmaceutical composition for use in same |
| AR028039A1 (es) | 2000-05-03 | 2003-04-23 | Oncolytics Biotech Inc | Remocion de reovirus de celulas neoplasticas intermediadas por ras a partir de composiciones celulares mixtas |
| US7306902B2 (en) * | 2002-06-28 | 2007-12-11 | Oncolyties Biotech Inc. | Oncolytic viruses as phenotyping agents for neoplasms |
| AR028040A1 (es) * | 2000-05-03 | 2003-04-23 | Oncolytics Biotech Inc | Remocion de virus de celulas neoplasticas a partir de composiciones celulares mixtas |
| US20020037543A1 (en) * | 2000-06-26 | 2002-03-28 | Atkins Harold L. | Purging of cells using viruses |
| WO2002004596A2 (fr) | 2000-07-07 | 2002-01-17 | President And Fellows Of Harvard College | Diagnostic et traitement de cellules cancereuses a l'aide de virus mutants |
| MXPA03004029A (es) | 2000-11-09 | 2004-02-12 | Oncolytics Biotech Inc | Metodos para tratamiento de trastornos proliferativos celulares. |
| US20030138405A1 (en) * | 2001-04-17 | 2003-07-24 | Juan Fueyo | Conditionally replicative adenovirus to target the Rb and Rb-related pathways |
-
2003
- 2003-06-24 US US10/602,024 patent/US7306902B2/en not_active Expired - Lifetime
- 2003-06-25 EP EP07021569A patent/EP1890151B1/fr not_active Expired - Lifetime
- 2003-06-25 SI SI200332164T patent/SI1890151T1/sl unknown
- 2003-06-25 JP JP2004516379A patent/JP2005531306A/ja active Pending
- 2003-06-25 BR BR0311983-1A patent/BR0311983A/pt not_active IP Right Cessation
- 2003-06-25 PT PT07021569T patent/PT1890151E/pt unknown
- 2003-06-25 NZ NZ537116A patent/NZ537116A/en unknown
- 2003-06-25 CA CA2487824A patent/CA2487824C/fr not_active Expired - Lifetime
- 2003-06-25 MX MXPA04012414A patent/MXPA04012414A/es active IP Right Grant
- 2003-06-25 AT AT07021569T patent/ATE555388T1/de active
- 2003-06-25 DK DK03737795T patent/DK1520175T3/da active
- 2003-06-25 EP EP03737795A patent/EP1520175B1/fr not_active Expired - Lifetime
- 2003-06-25 DK DK07021569.4T patent/DK1890151T3/da active
- 2003-06-25 AU AU2003245760A patent/AU2003245760B2/en not_active Expired
- 2003-06-25 AT AT03737795T patent/ATE377754T1/de not_active IP Right Cessation
- 2003-06-25 WO PCT/CA2003/000951 patent/WO2004003562A2/fr active Application Filing
- 2003-06-25 DE DE60317331T patent/DE60317331T2/de not_active Expired - Lifetime
- 2003-06-25 ES ES03737795T patent/ES2292981T3/es not_active Expired - Lifetime
- 2003-06-25 ES ES07021569T patent/ES2385845T3/es not_active Expired - Lifetime
- 2003-06-25 CN CN03815353.XA patent/CN1666105B/zh not_active Expired - Lifetime
- 2003-06-26 TW TW092117377A patent/TWI327167B/zh not_active IP Right Cessation
- 2003-06-26 TW TW098135545A patent/TWI334444B/zh not_active IP Right Cessation
- 2003-06-26 AR ARP030102317A patent/AR039768A1/es unknown
- 2003-06-26 TW TW098118162A patent/TWI402345B/zh not_active IP Right Cessation
-
2004
- 2004-12-01 IL IL16549804A patent/IL165498A0/xx active IP Right Grant
-
2005
- 2005-04-18 HK HK05103306A patent/HK1069877A1/xx not_active IP Right Cessation
-
2007
- 2007-05-30 US US11/807,771 patent/US20080014577A1/en not_active Abandoned
-
2008
- 2008-06-26 HK HK08107121.9A patent/HK1112509A1/xx not_active IP Right Cessation
- 2008-08-28 AU AU2008207579A patent/AU2008207579B2/en not_active Expired
-
2010
- 2010-01-05 US US12/652,289 patent/US8222036B2/en not_active Expired - Lifetime
-
2012
- 2012-06-04 IL IL220139A patent/IL220139A/en active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1520175T3 (da) | Oncolytiske vira som midler til fænotypebestemmelse af neoplasmer | |
| DK1423391T3 (da) | Pyrrolopyrimidiner som midler til inhibering af cysteinproteaser | |
| DK1730110T3 (da) | Svovlforbindelser som inhibitorer af hepatitis C-virus NS3-serinprotease | |
| NO20043642L (no) | Heterocykiske tripeptider som hepatitt C inhibitorer | |
| IS8476A (is) | Lifrarbólgu C-veirutálmar | |
| DK3395339T3 (da) | Hurtigt opløsende formulering af cinacalcet-hcl | |
| DK1562589T3 (da) | Diaminotriazoler der er nyttige som inhibitorer af proteinkinaser | |
| DK1402075T3 (da) | Udvikling af egnede mutationer til svækkelse af dengue-vira samt kimære dengue-vira | |
| DK1492785T3 (da) | 2-hydroxy-3-heteroarylindol-derivater som GSK3-inhibitorer | |
| IS2761B (is) | Ný amínóbensófenónefnasambönd | |
| NO20023283D0 (no) | Flammestopper | |
| DK1802579T3 (da) | Derivater af 3-arylaminopyridin | |
| DK1504126T3 (da) | Fremgangsmåde til regulering af genekspression | |
| DK2060570T3 (da) | Som modulatorer af dopamin-d3-receptorer anvendelige azabicyclo(3.1.0)hexanderivater | |
| DK1542977T3 (da) | 2,5-dioxoimidazolidin-4-ylacetamider og analoger som inhibitorer af metalloproteinase MMP12 | |
| DK1948176T3 (da) | Diarylurinstoffer til behandling af pulmonær hypertension | |
| DK1997512T3 (da) | Fremgangsmåder til behandling af TWEAK-relaterede tilstande | |
| DE602004025775D1 (de) | Innengekühltes strömungsleitendes Komponent | |
| DK1401828T3 (da) | N-Formylhydroxylaminforbindelser som inhibitorer af PDF | |
| DK1660090T3 (da) | Quinazolin-analoger som receptor-tyrosinkinase-inhibitorer | |
| ATE398450T1 (de) | Derivate von aryl-chinazolin/aryl-2amino-phenyl- methanon zurförderung der freisetzung von parathormon | |
| DK1773787T3 (da) | Fremgangsmåde til fremstilling af 3-phenyl(thio)uraciler og -dithiouraciler | |
| DE602004012448D1 (de) | Morpholinylhaltige benzimidazole als inhibitoren der replikation von respiratory syncytial virus | |
| DK1438289T3 (da) | Indolderivater som cox II-inhibitorer | |
| DK1516540T3 (da) | Anvendelse af vitamin D-forbindelser |